A viral model for corneal scarring and neovascularization following ocular infection of rabbits with a herpes simplex virus type 1 (HSV-1) mutant

Cornea

Volumn 24, Issue 4, 2005, Pages 460-466

  Barsam, Charles A ^a,c   Brick, David J ^a   Jones, Clinton ^b   Wechsler, Steven L ^a   Perng, Guey Chuen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Corneal scarring; HSV 1; Neovascularization; Rabbit ocular model

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEAL SCARRING; DISEASE MODEL; EYE INFECTION; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECURRENT DISEASE; SCAR FORMATION; VIRUS INFECTION; VIRUS REACTIVATION; VISUAL IMPAIRMENT;

ANIMALS; CICATRIX; CORNEA; CORNEAL DISEASES; DISEASE MODELS, ANIMAL; GENOME, VIRAL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; VIRUS LATENCY;

EID: 17844394175     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000138833.34865.39     Document Type: Article

References (61)

1. Liesegang TJ, Melton LJ 3rd, Daly PJ, et al. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155-1159.
2. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357:1513-1518.
3. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26:541-553; quiz 554-555.
4. Roizman B, Whitley RJ. The nine ages of herpes simplex virus. Herpes. 2001;8:23-27.
5. Streilein JW. Immune regulation and the eye: a dangerous compromise. FASEB J. 1987;1:199-208.
6. Meyers RL. Immunology of herpes simplex virus infection. Int Ophthalmol Clin. 1975;15:37-47.
7. Thomas J, Rouse BT. Immunopathogenesis of herpetic ocular disease. Immunol Res. 1997;16:375-386.
8. Deshpande SP, Zheng M, Lee S, et al. Mechanisms of pathogenesis in herpetic immunoinflammatory ocular lesions. Vet Microbiol. 2002;86: 17-26.
9. Davey MP, Rosenbaum JT. The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol. 2000;129:235-243.
10. Thomas J, Kanangat S, Rouse BT. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J Interferon Cytokine Res. 1998;18:681-690.
11. Liesegang TJ. Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1160-1165.
12. Roizman B, and Sears AE. Herpes simplex viruses and their replication. In: Howley BNFaDMKaPM, ed. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996.
13. Leib DA, Bogard CL, Kosz-Vnenchak M, et al. A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J Virol. 1989;63:2893-2900.
14. Block TM, Deshmane S, Masonis J, et al. An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers. Virology. 1993;192:618-630.
15. Perng GC, Dunkel EC, Geary PA, et al. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol. 1994;68: 8045-8055.
16. Feldman LT, Ellison AR, Voytek CC, et al. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci USA. 2002;99:978-983.
17. Ahmed M, Lock M, Miller CG, et al. Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo. J Virol. 2002;76:717-729.
18. Perng GC, Jones C, Ciacci-Zanella J, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science. 2000;287:1500-1503.
19. Inman M, Perng GC, Henderson G, et al. Region of herpes simplex virus type 1 latency-associated transcript sufficient for wild-type spontaneous reactivation promotes cell survival in tissue culture. J Virol. 2001;75: 3636-3646.
20. Jin L, Peng W, Perng GC, et al. Identification of herpes simplex virus type 1 latency-associated transcript sequences that both inhibit apoptosis and enhance the spontaneous reactivation phenotype. J Virol. 2003;77:6556-6561.
21. Jones C. Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin Microbiol Rev. 2003;16:79-95.
22. Ciacci-Zanella J, Stone M, Henderson G, et al. The latency-related gene of bovine herpesvirus 1 inhibits programmed cell death. J Virol. 1999;73: 9734-9740.
23. Jiang Y, Hossain A, Winkler MT, et al. A protein encoded by the latency-related gene of bovine herpesvirus 1 is expressed in trigeminal ganglionic neurons of latently infected cattle and interacts with cyclin-dependent kinase 2 during productive infection. J Virol. 1998;72:8133-8142.
24. Drolet BS, Perng GC, Cohen J, et al. The region of the herpes simplex virus type 1 LAT gene involved in spontaneous reactivation does not encode a functional protein. Virology. 1998;242:221-232.
25. Perng GC, Maguen B, Jin L, et al. A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels. J Virol. 2002; 76:1224-1235.
26. Sack RA, Nunes I, Beaton A, et al. Host-defense mechanism of the ocular surfaces. Biosci Rep. 2001;21:463-480.
27. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611-613.
28. Epstein RJ, Stalling RD, Hendricks RL, et al. Corneal neovascularization. Pathogenesis and inhibition. Cornea. 1987;6:250-257.
29. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull WHO. 2001;79:214-221.
30. Whitcher JP, Srinivasan M, Upadhyay MP. Prevention of corneal ulceration in the developing world. Int Ophthalmol Clin. 2002;42:71-77.
31. Bainbridge JW, Mistry AR, Thrasher AJ, et al. Gene therapy for ocular angiogenesis. Clin Sci (Lond). 2003;104:561-575.
32. Harney BA, Easty DL, Skinner GR. Investigation of a sub-unit vaccine using an animal model of herpes simplex keratitis. Trans Ophthalmol Soc UK. 1983;103:342-346.
33. Anderson JR, Field HJ. An animal model of ocular herpes. Keratitis, retinitis and cataract in the mouse. Br J Exp Pathol. 1984;65:283-297.
34. Horowitz Z, Strome M, Fried MP. An animal model for the assessment of microvascular patency. Head Neck Surg. 1983;6:575-580.
35. Gole GA, Browning J, Bits SM. The mouse model of oxygen-induced retinopathy: a suitable animal model for angiogenesis research. Doc Ophthalmol. 1990;74:163-169.
36. Liekens S, Verbeken E, Vandeputte M, et al. A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res. 1999;59:2376-2383.
37. Wang B, Shi Q, Abbruzzese JL, et al. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Pancreatol. 2001;29:37-46.
38. Perng GC, Thompson RL, Sawtell NM, et al. An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J Virol. 1995;69:3033-3041.
39. Perng GC, Ghiasi H, Slanina SM, et al. High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation. J Virol. 1996;70:2883-2893.
40. Perng GC, Esmaili D, Slanina SM, et al. Three herpes simplex virus type 1 latency-associated transcript mutants with distinct and asymmetric effects on virulence in mice compared with rabbits. J Virol. 2001;75: 9018-9028.
41. Ghiasi H, Hofman FM, Wallner K, et al. Corneal macrophage infiltrates following ocular herpes simplex virus type 1 challenge vary in BALB/c mice vaccinated with different vaccines. Vaccine. 2000;19:1266-1273.
42. Perng GC, Slanina SM, Yukht A, et al. The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits. J Virol. 2000;74:1885-1891.
43. Cook SD, Hill JM, Lynas C, et al. Latency-associated transcripts in corneas and ganglia of HSV-1 infected rabbits. Br J Ophthalmol. 1991;75: 644-648.
44. Cook SD, Hill JH. Herpes simplex virus: molecular biology and the possibility of conical latency. Surv Ophthalmol. 1991;36:140-148.
45. Liescgang TJ. Biology and molecular aspects of herpes simplex and varicella-zoster virus infections. Ophthalmology. 1992;99:781-799.
46. Stevens JG, Wagner EK, Devi-Rao GB, et at. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235:1056-1059.
47. Rock DL, Nesburn AB, Ghiasi H, et al. Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol. 1987;61:3820-3826.
48. Whitley RJ, Miller RL. Immunulogic approach to herpes simplex virus. Viral Immunol. 2001;14:111-118.
49. Rouse BT, Gierynska M. Immunity to herpes simplex virus: a hypothesis. Herpes. 2001;8(Suppl 1):2A-5A.
50. Bloom DC, Devi-Rao GB, Hill JM, et al. Molecular analysis of herpes simplex virus type 1 during epinephrine-induced reactivation of latently infected rabbits in vivo. J Virol. 1994;68:1283-1292.
51. Perng GC, Slanina SM, Yuklit A, et al. A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation. J Virol. 1999;73:920-929.
52. Lovato L, Inman M, Henderson G, et al. Infection of cattle with a bovine herpesvirus 1 strain that contains a mutation in the latency-related gene leads to increased apoptosis in trigeminal ganglia during the transition from acute infection to latency. J Virol. 2003;77:4848-4857.
53. Devireddy LR, Jones C. Alternative splicing of the latency-related transcript of bovine herpesvirus 1 yields RNAs containing unique open reading frames. J Virol. 1998;72:7294-7301.
54. Carr DJ, Harle P, Gebhardt BM. The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med (Maywood). 2001;226:353-366.
55. Mott KR, Osorio N, Jin L, et al. The bovine herpesvirus-1 LR ORF2 is critical for this gene's ability to restore the high wild-type reactivation phenotype to a herpes simplex virus-1 LAT null mutant. J Gen Virol. 2003;84:2975-2985.
56. Gotisch JD, Akpek EK. Topical cyclosporin stimulates neovascularization in resolving sterile rheumatoid central corneal ulcers. Trans Am Ophthalmol Soc. 2000;98:81-87; discussion 87-90.
57. Hendricks RL. An immunologist's view of herpes simplex keratitis: Thygeson Lecture 1996, presented at the Ocular Microbiology and Immunology Group meeting, October 20, 1996. Cornea. 1997;16: 503-506.
58. Kremer I, Cohen EJ, Eagle RC Jr, et al. Histopathologic evaluation of stromal inflammation in Acanthamoeba keratitis. CLAO J. 1994;20: 45-48.
59. Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis. Cornea. 2001;20:123-128.
60. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.
61. Douglas RG Jr, Couch RB. A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol. 1970;104:289-295.